Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN)

Investment analysts at Cantor Fitzgerald began coverage on shares of Septerna (NASDAQ:SEPN) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 122.22% from the company’s previous close.

Separately, TD Cowen started coverage on shares of Septerna in a research note on Tuesday. They issued a “buy” rating on the stock.

Septerna Stock Performance

SEPN opened at $22.50 on Tuesday. Septerna has a 12 month low of $18.62 and a 12 month high of $26.34.

Insider Activity at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of Septerna stock in a transaction on Monday, October 28th. The shares were acquired at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.